Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies

SIMPLE SUMMARY: HER2-positive metastatic breast cancer remains a nearly incurable disease. In this sense, new treatments have been developed in recent years. On the one hand, drug conjugates have been reformulated and, on the other hand, the combination of anti-HER2 therapies with new drugs has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Tapia, Marta, Hernando, Cristina, Martínez, María Teresa, Burgués, Octavio, Tebar-Sánchez, Cristina, Lameirinhas, Ana, Ágreda-Roca, Anna, Torres-Ruiz, Sandra, Garrido-Cano, Iris, Lluch, Ana, Bermejo, Begoña, Eroles, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527351/
https://www.ncbi.nlm.nih.gov/pubmed/37760491
http://dx.doi.org/10.3390/cancers15184522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527351/
https://www.ncbi.nlm.nih.gov/pubmed/37760491
http://dx.doi.org/10.3390/cancers15184522

Ejemplares similares